VS-041
Heart Failure with Preserved Ejection Fraction (HFpEF)
Phase 1Active
Key Facts
Indication
Heart Failure with Preserved Ejection Fraction (HFpEF)
Phase
Phase 1
Status
Active
Company
About Vasa Therapeutics
Vasa Therapeutics is a private, preclinical-to-clinical stage biotech developing transformative small molecule therapies for diseases of cardiovascular aging and related disorders. Its lead asset, VS-041, is a narrow-spectrum MMP-2/9 inhibitor with FDA Fast Track designation currently in a Phase 1 Proof-of-Mechanism (PoM) study for Heart Failure with Preserved Ejection Fraction (HFpEF). The company leverages a founder-led team with a strong drug development track record and is backed by seed investors and non-dilutive EU grant funding, positioning it to advance a pipeline targeting significant unmet needs in heart failure, peripheral artery disease, and sarcopenia.
View full company profileTherapeutic Areas
Other Heart Failure with Preserved Ejection Fraction (HFpEF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | Clinical Feasibility |
| MANP | E-Star BioTech | Phase 1/2 |
| ALLAY-HF | Alleviant Medical | Pivotal Trial |
| PEGylated Pirfenidone | i-Cordis | Pre-clinical |
| Neucardin® | Zensun Sci & Tech | Phase 2 |
| SAVM Procedure | Axon Therapies | Phase 2 |
| SRD001 (inferred) | Sardocor | Phase 1 |
| STM-01 | Secretome Therapeutics | Phase 1 |